Table 2: Phase III studies on intravenous dose-dense paclitaxel.

StudyRegimenMedian PFS 
(m)
Median 
OS  
(m)
Adverse effectsComments




Katsumata et al., 2009 [21]  
Katsumata et al., 2013 [22]  
Harano et al., 2014 [23]
JGOG 3016 631
  

(i) Haematological toxicity higher in dose dense-21.1 versus 9.4%
Lower treatment completion in dose-dense 63 versus 48% 
Frequent episodes of delay in dose-dense 76 versus 67% 
Dose reductions in dose-dense 48 versus 35% 
No significant difference in overall QOL between both groups ()
Paclitaxel 80 mg/m2 D1, 8, 15 + carboplatin AUC 6, 3 weekly versus  
Paclitaxel 180 mg/m2 + carboplatin AUC 6, 3 weekly
31228.2100.5
Both given for 6–9 cycles 31917.562.2









Chan et al., 2013 [24]
GOG-262



(i) Higher frequency of grade 3 anaemia (40.8 versus 15.7%, ), 
grade 2 sensory neuropathy (25.9 versus 17.8%, ) but lower incidence of neutropenia (72 versus 83%, )
Paclitaxel 80 mg/m2 D1, 8, 15 + carboplatin AUC 6, 3 weekly versus  
Paclitaxel 175 mg/m2 + carboplatin AUC 6, 3 weekly
34614.8NR
Both given for 6 cycles34614.3NR
Bevacizumab given optionally112  
(did not receive bevazicumab)
14.2 vs 10.3





Pignata et al., 2014 [25]
MITO-7810(i) Lower incidence of grade 3-4 neutropenia (42 versus 50%), febrile neutropenia (<1 versus 3%, ), thrombocytopenia (1 versus 7%, ), and other nonhaematological toxicities such as alopecia, vomiting, renal dysfunction, and neuropathy


 Quality of life better in dose dense arm ()
Paclitaxel 60 mg/m2, weekly + carboplatin AUC 2, weekly versus  
Paclitaxel 175 mg/m2 + carboplatin AUC 6, 3 weekly
406
404
18.3 
17.3


: number of patients, m: months, D: day PFS: progression free survival, OS: overall survival, NA: not available in paper or abstract, and NR: not yet reached.
Survival rate at 2 years.